TB-500 is frequently mentioned alongside BPC-157 as a recovery-focused research peptide, and the two share a similar evidence profile: promising laboratory signals, but a thin human research record.
What It Is
TB-500 is a synthetic version of a fragment of thymosin beta-4, a naturally occurring protein involved in cell migration, wound healing, and blood vessel formation. It's studied for its potential role in tissue repair, distinct from BPC-157's specific origin in gastric protective research, though the two are often marketed together for overlapping recovery purposes.
Regulatory Status
Like BPC-157, TB-500 is not FDA-approved for any indication and was excluded from the FDA's list of substances eligible for 503A pharmacy compounding, based on an evidence review that found insufficient safety data to support that use. It is sold as a research chemical, explicitly not intended for human use.
What the Research Shows
Most available evidence comes from animal studies and cell-culture research examining wound healing, cardiac tissue repair following injury, and hair follicle activity. Thymosin beta-4 itself (the naturally occurring full protein, distinct from the synthetic TB-500 fragment sold commercially) has been studied in a small number of early-phase human trials for specific conditions like dry eye and certain wound types, but this shouldn't be conflated with human evidence for the synthetic fragment product actually sold under the TB-500 name, which remains essentially untested in controlled human trials.
Safety Considerations
Without controlled human trials, there's no established human dosing standard, no confirmed human side effect profile, and no long-term safety data. As with BPC-157, product quality from unregulated sellers is a separate, documented concern layered on top of the compound's own unknowns.
The Bottom Line
TB-500 sits in essentially the same evidentiary position as BPC-157: genuine scientific interest at the preclinical level, but a human research record too thin to support the confident recovery claims commonly made in its marketing.
A Note on Naming Confusion
Some marketing materials use "TB-500" and "thymosin beta-4" interchangeably, but the compound actually sold commercially is typically a synthetic fragment, not the identical full-length natural protein that appears in the limited early-phase human research on thymosin beta-4 itself. This distinction is easy to miss and worth checking specifically before assuming research on one applies directly to the other.
What a More Rigorous Path Forward Would Look Like
As with BPC-157, a meaningful shift in TB-500's evidence position would require registered human trials specifically evaluating the synthetic fragment product, not just further animal research or continued reliance on the separate, limited thymosin beta-4 studies. Checking ClinicalTrials.gov directly for either compound name, a habit encouraged throughout this site's research section, is a concrete way to track whether that evidence gap starts closing over time.